Under the Radar, page-490

Off topic to other threads so will fit well under this one.

Admedus made mention of being proud to be at the EuroPCR 2019, be nice to know if they presented during this convention, either with their TAVR IP and or any IP from its Adapt platform, wasn’t able to pin anything down for what ever reasons.

There was a YouTube clip titled ‘Best of PCR Innovators Day’, topic was The best innovations in the cardiovascular medicine’.

No single party was highlighted or named though, sobering comment made was ‘there are over 30 devices in the TAVR value replacement field’ under R&D!

Another comment made was the importance of ‘resilience’ factor, .... to the workability and recovery thereafter any procedure I presume (?). ..... Admedus TAVR perhaps ticking a couple of these boxes (?)

What may or may not make Admedus a standout (TAVR field very competitive) is it’s Adapt platform IP especially if ‘first in its field’, WP did make mention that no major player had yet announced any IP that was compatible.

Best case scenario; does this help Admedus out in the very immediate future?, as in a party putting their hand up to claim this IP and be ‘first in the field’ to commercialise?

That Admedus may be in a poor bargaining position may be negated to some extent if the IP is indeed ‘first in its field’, R&D compelling and this party wishes to cut directly to the chase.

Again best case scenario would see more than one interested party in this IP.

For that particular entity they should hit the ground running, RIs hopefully at a distance behind!


WPs mettle will certainly be highlighted, despite Admedus being in the position it is in, for whatever reasons, if on resume of trading funds for a minimum of one year are upfront with a shareholder mix that will see RIs at a 25% plus stake and a sp that reflects a positive sentiment from the market.

There is some hope, understated perhaps is the importance of not being in debt to SB, or anybody else for that matter, company does have, arguably, World wide recognised IP, which unfortunately was not successfully commercialised in a timely manner and been the causation off its current position, imo.

Admedus has taken far more backward steps then forward steps, the future will dictate whether its finally forward from here or not, on resume of trading.

Resume of trading, after details of recapitalisation revealed will soon show the consequences, good, bad or indifferent to RIs!